EQS-Adhoc: Cytos Biotechnology AG will become debt-free

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Financing Cytos Biotechnology AG will become debt-free

2015-05-04 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement.

=--------------------------------------------------------------------

Cytos will become debt-free.

- Restructuring proposal final and binding to convert all bonds into equity

- Settlement with loan note holders eliminates all claims from loan notes

Schlieren (Zurich), Switzerland, May 4, 2015 - Cytos Biotechnology Ltd ("Cytos") today announced that the convertible bond restructuring approved by the superior composition authority of creditors of the canton of Zurich ("Obere Kantonale Nachlassbehörde") has become valid and binding ("rechtskräftig") and that the bonds can be converted into shares. An extraordinary Shareholders' Meeting approved the required capital increase already and the conversion will take place within the first half of May 2015. The incentive payment of CHF 25.00 per bond will be effected at the same time and will be free of any withholding tax.

Further, a settlement with the convertible loan note holders was reached eliminating all claims from the convertible loan notes immediately after the conversion of the bonds into equity. In exchange, Cytos will make a final payment of around CHF 4.4 million to the loan notes holders once it has received the CHF 4 million from Novartis for the buy-out of CAD106 as well as some payments from OnCore.

As a result of the above, Cytos will very soon be free of any debt upon completion of the bond conversion and the settlement of the claims with the loan note holders.

For further information, please contact:

Cytos Biotechnology Ltd Harry Welten, MBA Chief Financial Officer Tel: +41 44 733 46 46 harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com End of ad hoc announcement

+++++ Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=GNFWELWUUT Document title: Cytos_Press_E_150504

=--------------------------------------------------------------------

2015-05-04 News transmitted by EQS Schweiz AG. www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

=--------------------------------------------------------------------

Language: English Company: Cytos Biotechnology AG Wagistr. 25 8952 Schlieren Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@cytos.com Internet: www.cytos.com ISIN: CH0011025217, CH0029060735 Valor: - Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News-Service =-------------------------------------------------------------------- 352045 2015-05-04 (END) Dow Jones Newswires

   May 04, 2015 01:00 ET (05:00 GMT)- - 01 00 AM EDT 05-04-15